FATE THERAPEUTICS INC. 2023-2024 Proxy Voting Records

Description as filed by funds: Election of Class II Directors: Michael Lee

FATE THERAPEUTICS INC.’s own tally for this item (“Elect Director: Michael Lee”): 90,262,212 for, 1,188,429 withheld, per its Form 8-K filed June 7, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “All matters submitted to a vote of the Company's stockholders at the Annual Meeting were approved and all director nominees were elected.”
Support: 99% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 63 asset managers below reported 26,563,963 for, 385,404 withheld.

Showing the 25 largest of 63 asset managers. See all 63 in the interactive database.

Description as filed by funds: Election of Class II Directors: William H. Rastetter, Ph.D.

FATE THERAPEUTICS INC.’s own tally for this item (“Elect Director: William H. Rastetter, Ph.D.”): 82,587,977 for, 8,440,527 withheld, per its Form 8-K filed June 7, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “All matters submitted to a vote of the Company's stockholders at the Annual Meeting were approved and all director nominees were elected.”
Support: 91% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 63 asset managers below reported 20,381,803 for, 6,567,564 withheld.

Showing the 25 largest of 63 asset managers. See all 63 in the interactive database.

The 62 asset managers below reported 26,259,453 for, 689,610 withheld. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

Showing the 25 largest of 62 asset managers. See all 62 in the interactive database.

Description as filed by funds: To approve an amendment to the Company's Amended and Restated Certificate of Incorporation to include an officer exculpation provision that limits the liability of certain of its officers as permitted under current Delaware law.

The 63 asset managers below reported 26,036,836 for, 877,113 against, 35,418 abstained. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

Showing the 25 largest of 63 asset managers. See all 63 in the interactive database.

Description as filed by funds: To approve the adjournment of the Annual Meeting to the extent there are insufficient votes at the Annual Meeting to approve any of the above proposals.

FATE THERAPEUTICS INC.’s own tally for this item (“(vi) Approval of the adjournment of the Annual Meeting to the extent there are insufficient votes at the Annual Meeting to approve any of the above proposals.”): 57,506,789 for, 33,547,222 against, per its Form 8-K filed June 7, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 63% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 63 asset managers below reported 16,392,183 for, 10,521,766 against, 35,418 abstained.

Showing the 25 largest of 63 asset managers. See all 63 in the interactive database.

Description as filed by funds: To approve the amendment and restatement of the Company's 2022 Stock Option and Incentive Plan to increase the number of shares of common stock reserved for issuance thereunder.

FATE THERAPEUTICS INC.’s own tally for this item (“(v) Approval of the 2022 A&R Plan to increase the number of shares of common stock reserved for issuance thereunder.”): 59,762,463 for, 31,270,315 against, per its Form 8-K filed June 7, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 66% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 64 asset managers below reported 16,763,054 for, 10,107,654 against, 78,817 abstained.

Showing the 25 largest of 64 asset managers. See all 64 in the interactive database.

Description as filed by funds: To approve, on an advisory basis, the compensation of the Company's named executive officers as disclosed in the proxy statement.

FATE THERAPEUTICS INC.’s own tally for this item (“(iii) Non-binding Advisory Vote on Compensation of Named Executive Officers.”): 65,401,635 for, 25,615,148 against, per its Form 8-K filed June 7, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 72% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Also reported under other wordings, matched to the same row of FATE THERAPEUTICS INC.’s official tally and shown with their own fund figures; their managers are not in the figures or the table on this card: “Advisory Vote to Ratify Named Executive Officers' Compensation” (5 managers, 13,341 for, 3,451,652 against).

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports, all 63 managers: 21,860,580 for, 5,009,970 against, 78,817 abstained. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports, all 154 managers: 46,606,245 for, 18,541,610 against, 316,220 abstained, 3,000 not voted. Showing the 25 largest; see all in the interactive database.

Description as filed by funds: To ratify the appointment of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2024.

FATE THERAPEUTICS INC.’s own tally for this item (“(ii) Ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024.”): 96,478,449 for, 113,003 against, per its Form 8-K filed June 7, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 99.8% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 63 asset managers below reported 26,903,311 for, 10,638 against, 35,418 abstained.

Showing the 25 largest of 63 asset managers. See all 63 in the interactive database.